References
- Acmaz G, Aksoy H, Albayrak E, et al (2014). Evaluation of endometrial precancerous lesions in postmenopausal obese women-a high risk group? Asian Pac J Cancer Prev, 15, 195-8. https://doi.org/10.7314/APJCP.2014.15.1.195
- Balik G, Kagitci M, Ustuner I, et al (2013). Which endometrial pathologies need intraoperative frozen sections? Asian Pac J Cancer Prev, 14, 6121-5. https://doi.org/10.7314/APJCP.2013.14.10.6121
- Bansal N, Yendluri V, Wenham RM (2009). The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies, cancer control J Moffitt Cancer Center, 16, 8.
- Cetinkaya K, Atalay F, Bacinoglu A (2014). Risk factors of lymph node metastases with endometrial carcinoma Asian Pac J Cancer Prev, 15, 6353. https://doi.org/10.7314/APJCP.2014.15.15.6353
- Clifford SC, Astuti D, Hooper L, et al (2001). The pVHLassociated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma, Oncogene, 20, 5067-74. https://doi.org/10.1038/sj.onc.1204602
- Epstein AC, Gleadle JM, McNeill LA, et al (2001). C elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell, 107, 43-54. https://doi.org/10.1016/S0092-8674(01)00507-4
- Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009). Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship, Gynecol Oncol, 114, 121-7. https://doi.org/10.1016/j.ygyno.2009.03.039
- Garcia-Dios DA, Lambrechts D, Coenegrachts L, et al (2013). High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma Gynecol Oncol, 128, 327-34. https://doi.org/10.1016/j.ygyno.2012.11.037
-
Hebert C, Norris K, Parashar P, et al (2006). Hypoxia-inducible factor-1
${\alpha}$ polymorphisms and TSC1/2 mutations are complementary in head and neck cancers Molecular Cancer, 5, 3. https://doi.org/10.1186/1476-4598-5-3 - Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New England J Med, 350, 2335-42. https://doi.org/10.1056/NEJMoa032691
- Jiang XF, Tang QL, Zou Y, et al (2014). Does HBV infection increase risk of endometrial carcinoma? Asian Pac J Cancer Prev, 15, 713-6. https://doi.org/10.7314/APJCP.2014.15.2.713
- Kung AL, Klco JM, Kaelin WG, Livingston DM (2000). Suppression of tumor growth through disruption of hypoxiainducible transcription, Nature Med, 6, 1335-40. https://doi.org/10.1038/82146
-
Ling TS, Shi RH, Zhang GX, et al (2005). Common single nucleotide polymorphism of hypoxia-inducible factor-1
${\alpha}$ and its impact on the clinicopathological features of esophageal squamous cell carcinoma Chinese J Digestive Diseases, 6, 155-8. https://doi.org/10.1111/j.1443-9573.2005.00223.x - Liu FS (2007). Molecular carcinogenesis of endometrial cancer Taiwanese J Obstet Gynecol, 46, 26-32. https://doi.org/10.1016/S1028-4559(08)60102-3
- Mazurek A, Kuc P (2005). Angiogenesis-prognostic factor in patients with endometrial cancer Ginekologia Polska, 76, 838-45
- Minaguchi T, Yoshikawa H, Oda K, et al (2001). PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas Clinical Cancer Res, 7, 2636-42.
- Myatt SS, Wang J, Monteiro LJ, et al (2010). Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer Cancer Res, 70, 367-77.
- Neubauer NL, Lurain JR (2011). The role of lymphadenectomy in surgical staging of endometrial cancer. Internl J Surg Oncol, 2011, 814649.
- Okuda T, Sekizawa A, Purwosunu Y, et al (2010). Genetics of endometrial cancers. Obstet Gynecol Internl.
- Prat J, Gallardo A, Cuatrecasas M, Catasus L (2007). Endometrial carcinoma: pathology and genetics. Pathology, 39, 72-87. https://doi.org/10.1080/00313020601136153
- Rasila K, Burger R, Smith H, Lee F, Verschraegen C (2005). Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Internl J Gynecol Cancer, 15, 710-26. https://doi.org/10.1111/j.1525-1438.2005.00132.x
- Sun H, Enomoto T, Fujita M, et al (2001). Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol, 115, 32-8. https://doi.org/10.1309/7JX6-B9U9-3P0R-EQNY
-
Tanimoto K, Yoshiga K, Eguchi H, et al (2003). Hypoxiainducible factor-1
${\alpha}$ polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis, 24, 1779-83. https://doi.org/10.1093/carcin/bgg132 - Thanapprapasr D, Thanapprapasr K (2013). Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev, 14, 3419-23. https://doi.org/10.7314/APJCP.2013.14.6.3419
- Wang HL, Liu MM, Ma X, et al (2014). Expression and effects of JMJD2A histone demethylase in endometrial carcinoma. Asian Pac J Cancer Prev, 15, 3051. https://doi.org/10.7314/APJCP.2014.15.7.3051
- Zeng YW, Yang JZ, Pu XY, et al (2013). Strategies of functional food for cancer prevention in human beings. Asian Pac J Cancer Prev, 14, 1585-92. https://doi.org/10.7314/APJCP.2013.14.3.1585
-
Zhao T, Lv J, Zhao J, Nzekebaloudou M (2009). Hypoxiainducible factor-1
${\alpha}$ gene polymorphisms and cancer risk: a meta-analysis. J Experimental Clin Cancer Res, 28, 159. https://doi.org/10.1186/1756-9966-28-159 - Zhu XL, Ai ZH, Wang J, et al (2012). Weighted gene coexpression network analysis in identification of endometrial cancer prognosis markers. Asian Pac J Cancer Prev, 13, 4607-11. https://doi.org/10.7314/APJCP.2012.13.9.4607